MA27745A1 - Derives d'acide benzoylureidopyridyl-piperidine et pyrrolidinecarboxylique substitues, methode de production de ceux-ci et utilisation de ceux-ci. - Google Patents

Derives d'acide benzoylureidopyridyl-piperidine et pyrrolidinecarboxylique substitues, methode de production de ceux-ci et utilisation de ceux-ci.

Info

Publication number
MA27745A1
MA27745A1 MA28485A MA28485A MA27745A1 MA 27745 A1 MA27745 A1 MA 27745A1 MA 28485 A MA28485 A MA 28485A MA 28485 A MA28485 A MA 28485A MA 27745 A1 MA27745 A1 MA 27745A1
Authority
MA
Morocco
Prior art keywords
benzoylureidopyridyl
piperidine
substituted
acid derivatives
producing
Prior art date
Application number
MA28485A
Other languages
English (en)
Inventor
Karl Schoenafinger
Dieter Kadereit
Elisabeth Defossa
Andreas Herling
Thomas Klabunde
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27745A1 publication Critical patent/MA27745A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des composés de formule (I) dans laquelle les groupes ont la signification indiquée dans la description, ainsi qu'à leurs sels physiologiquement acceptables. Ces composés peuvent par exemple servir de médicaments pour prévenir et traiter un diabète de type 2.
MA28485A 2003-03-07 2005-09-07 Derives d'acide benzoylureidopyridyl-piperidine et pyrrolidinecarboxylique substitues, methode de production de ceux-ci et utilisation de ceux-ci. MA27745A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10309929A DE10309929B4 (de) 2003-03-07 2003-03-07 Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
MA27745A1 true MA27745A1 (fr) 2006-02-01

Family

ID=32945839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28485A MA27745A1 (fr) 2003-03-07 2005-09-07 Derives d'acide benzoylureidopyridyl-piperidine et pyrrolidinecarboxylique substitues, methode de production de ceux-ci et utilisation de ceux-ci.

Country Status (18)

Country Link
EP (1) EP1603895B1 (fr)
JP (1) JP2006519795A (fr)
KR (1) KR20050108487A (fr)
CN (1) CN1759109A (fr)
AT (1) ATE386735T1 (fr)
AU (1) AU2004218267A1 (fr)
BR (1) BRPI0408148A (fr)
CA (1) CA2518322A1 (fr)
CO (1) CO5690587A2 (fr)
DE (2) DE10309929B4 (fr)
HR (1) HRP20050779A2 (fr)
MA (1) MA27745A1 (fr)
MX (1) MXPA05009122A (fr)
NO (1) NO20054418L (fr)
PL (1) PL377293A1 (fr)
RU (1) RU2005131011A (fr)
WO (1) WO2004078743A1 (fr)
ZA (1) ZA200506119B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (fr) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase
WO2006055462A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
WO2006055435A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AU2010303670A1 (en) * 2009-10-06 2012-03-29 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3034004A1 (de) * 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
IL153273A0 (en) * 2000-06-09 2003-07-06 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10116768A1 (de) * 2001-04-04 2002-10-10 Aventis Pharma Gmbh Acylphenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10125567B4 (de) * 2001-05-25 2004-08-26 Aventis Pharma Deutschland Gmbh Carbonamid substituierte Phenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
EP1523471B1 (fr) * 2002-07-11 2009-09-16 Sanofi-Aventis Deutschland GmbH Acylurees substituees par uree et urethane, procedes permettant de les produire et leur utilisation comme medicaments
DE50312261D1 (de) * 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
ZA200506119B (en) 2006-11-29
AU2004218267A1 (en) 2004-09-16
ATE386735T1 (de) 2008-03-15
NO20054418L (no) 2005-09-23
CO5690587A2 (es) 2006-10-31
DE10309929A1 (de) 2004-12-02
CN1759109A (zh) 2006-04-12
KR20050108487A (ko) 2005-11-16
MXPA05009122A (es) 2005-10-20
DE10309929B4 (de) 2006-02-23
DE502004006253D1 (de) 2008-04-03
WO2004078743A1 (fr) 2004-09-16
CA2518322A1 (fr) 2004-09-16
BRPI0408148A (pt) 2006-03-01
PL377293A1 (pl) 2006-01-23
EP1603895B1 (fr) 2008-02-20
HRP20050779A2 (en) 2006-10-31
EP1603895A1 (fr) 2005-12-14
JP2006519795A (ja) 2006-08-31
RU2005131011A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
SE0102300D0 (sv) Compounds
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
MEP41408A (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
MA27232A1 (fr) Derives d'acide n-benzoylureidocinnamique, leurs procedes de preparation et leurs utilisations
TNSN05204A1 (en) 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MA27745A1 (fr) Derives d'acide benzoylureidopyridyl-piperidine et pyrrolidinecarboxylique substitues, methode de production de ceux-ci et utilisation de ceux-ci.
MA28340A1 (fr) Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments
BR0312586A (pt) Derivados de pirolidina como antagonistas e oxitocina
ATE424195T1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
DE60315597D1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
DE60209122D1 (de) Bernsteinsäurederivate
WO2004033416A3 (fr) Derives d'acyl-carboxyphenyl-uree a substitution carboxyalcoxy, leur procede de production et leur utilisation en tant que medicament
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
TNSN05008A1 (en) Heterocyclically substituted benzoylureas, method for their production and their use as medicaments.
DE50313293D1 (de) Polyencarbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE50310168D1 (de) Polyisoprenyl-benzophenon-derivate, verfahren zu ihrer herstellung und verwendung derselben